SCHEMBL6429427

SCHEMBL6429427

NC(=O)/C(N)=N/OC(=O)[C@H](CCCC1CCCCC1)CC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.38
MMP3 P08254 5/20 0.38
MMP1 P03956 4/20 0.38
EPHX1 P07099 1/20 0.34
BMP1 P13497 5/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
FKBP1A P62942 1/20 0.33
KDM5A P29375 2/20 0.33
PHF8 Q9UPP1 2/20 0.33
KDM2A Q9Y2K7 2/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM4A O75164 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6429432 1.00 MMP2 (0.38) MMP2MMP3MMP1EPHX1BMP1
SCHEMBL5759687 0.87 BMP1 (0.37) MMP2MMP3MMP1BMP1PDE4A
SCHEMBL5759691 0.87 BMP1 (0.37) MMP2MMP3MMP1BMP1PDE4A
SCHEMBL6430228 0.86 SMN1; SMN2 (0.34) MMP2EPHX1BMP1PDE4APDE4B
SCHEMBL6430229 0.86 SMN1; SMN2 (0.34) MMP2EPHX1BMP1PDE4APDE4B
SCHEMBL5760320 0.79 BMP1 (0.38) MMP2MMP3MMP1BMP1
SCHEMBL5760317 0.79 BMP1 (0.38) MMP2MMP3MMP1BMP1
SCHEMBL5760308 0.79 BMP1 (0.38) MMP2MMP3MMP1BMP1
SCHEMBL6430232 0.79 FKBP1A (0.33) MMP2MMP3EPHX1BMP1FKBP1A
SCHEMBL6428654 0.78 MAPT (0.35) MMP2MMP3MMP1BMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897306-B2 3-heterocyclylpropanohydroxamic acids PFIZER PRODUCTS, INC. (US) 2005-05-24 US disclosed
EP-1240152-B1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LTD (GB) 2004-12-08 EP disclosed
US-20030119807-A1 3-Heterocyclylpropanohydroxamic acids BAILEY SIMON (US) 2003-06-26 US disclosed
EP-1240152-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS Pfizer Limited (GB) 2002-09-18 EP disclosed
US-6448278-B2 ANTISCARRING AGENT PFIZER INC. 2002-09-10 US disclosed
US-20010021718-A1 Procollagen C-proteinase inhibitors PFIZER INC. 2001-09-13 US disclosed
WO-2001047901-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LIMITED (GB) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010021718-A1 Procollagen C-proteinase inhibitors MMP1, CTSL, PREP MMP2 16/4885MMP3 8/4885MMP1 1/4885
US-20030119807-A1 3-Heterocyclylpropanohydroxamic acids CPA1, MMP1, PREP MMP2 11/4885MMP3 18/4885MMP1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.